image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 10.23
-1.06 %
$ 2.9 B
Market Cap
63.94
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SHC stock under the worst case scenario is HIDDEN Compared to the current market price of 10.2 USD, Sotera Health Company is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SHC stock under the base case scenario is HIDDEN Compared to the current market price of 10.2 USD, Sotera Health Company is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SHC stock under the best case scenario is HIDDEN Compared to the current market price of 10.2 USD, Sotera Health Company is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SHC

image
$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
1.1 B REVENUE
4.88%
298 M OPERATING INCOME
7.57%
44.4 M NET INCOME
-13.58%
224 M OPERATING CASH FLOW
251.74%
-179 M INVESTING CASH FLOW
16.71%
-50.6 M FINANCING CASH FLOW
-19.01%
290 M REVENUE
1.66%
87.1 M OPERATING INCOME
8.25%
12.3 M NET INCOME
-27.46%
55.7 M OPERATING CASH FLOW
-41.72%
-65.9 M INVESTING CASH FLOW
-81.20%
-6.55 M FINANCING CASH FLOW
-714.43%
Balance Sheet Sotera Health Company
image
Current Assets 526 M
Cash & Short-Term Investments 277 M
Receivables 140 M
Other Current Assets 108 M
Non-Current Assets 2.55 B
Long-Term Investments 0
PP&E 1.06 B
Other Non-Current Assets 1.48 B
9.03 %4.57 %3.53 %34.65 %48.22 %Total Assets$3.1b
Current Liabilities 191 M
Accounts Payable 55.1 M
Short-Term Debt 22.8 M
Other Current Liabilities 113 M
Non-Current Liabilities 2.48 B
Long-Term Debt 2.33 B
Other Non-Current Liabilities 148 M
4.24 %87.29 %5.55 %Total Liabilities$2.7b
EFFICIENCY
Earnings Waterfall Sotera Health Company
image
Revenue 1.1 B
Cost Of Revenue 498 M
Gross Profit 602 M
Operating Expenses 305 M
Operating Income 298 M
Other Expenses 253 M
Net Income 44.4 M
1b1b1b1b800m800m600m600m400m400m200m200m001b(498m)602m(305m)298m(253m)44mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
54.73% GROSS MARGIN
54.73%
27.05% OPERATING MARGIN
27.05%
4.03% NET MARGIN
4.03%
10.96% ROE
10.96%
1.45% ROA
1.45%
4.00% ROIC
4.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sotera Health Company
image
200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)20192019202020202021202120222022202320232024202420252025
Net Income 44.4 M
Depreciation & Amortization 164 M
Capital Expenditures -179 M
Stock-Based Compensation 36.8 M
Change in Working Capital -42.6 M
Others -20.9 M
Free Cash Flow 45.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sotera Health Company
image
Wall Street analysts predict an average 1-year price target for SHC of $15.8 , with forecasts ranging from a low of $13 to a high of $18 .
SHC Lowest Price Target Wall Street Target
13 USD 27.08%
SHC Average Price Target Wall Street Target
15.8 USD 53.96%
SHC Highest Price Target Wall Street Target
18 USD 75.95%
Price
Max Price Target
Min Price Target
Average Price Target
181817171616151514141313121211111010May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Sotera Health Company
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
376 M USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results Rapid Sterility Testing yields product sterility test results in as little as 6 days and can be used for broadscale medical device and pharmaceutical product application Rapid Sterility Testing yields product sterility test results in as little as 6 days and can be used for broadscale medical device and pharmaceutical product application globenewswire.com - 1 month ago
Sotera Health Company (SHC) Q4 2024 Earnings Call Transcript Sotera Health Company (NASDAQ:SHC ) Q4 2024 Earnings Conference Call February 27, 2025 9:00 AM ET Company Participants Jason Peterson – Vice President of Investor Relations and Treasurer Michael Petras – Chairman and Chief Executive Officer Jon Lyons – Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Sean Dodge – RBC Capital Markets Luke Sergott – Barclays Casey Woodring – J.P. Morgan Brett Fishbin – KeyBanc Dave Windley – Jefferies Michael Polark – Wolfe Research Operator Good morning, and welcome to the Sotera Health Fourth Quarter and Full Year 2024 Conference Call. seekingalpha.com - 1 month ago
Compared to Estimates, Sotera Health (SHC) Q4 Earnings: A Look at Key Metrics Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 month ago
Sotera Health Company (SHC) Meets Q4 Earnings Estimates Sotera Health Company (SHC) came out with quarterly earnings of $0.21 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.26 per share a year ago. zacks.com - 1 month ago
Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2024 and its initial 2025 outlook. globenewswire.com - 1 month ago
Insights Into Sotera Health (SHC) Q4: Wall Street Projections for Key Metrics Evaluate the expected performance of Sotera Health (SHC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 1 month ago
Sotera Health Announces Fourth-Quarter and Full-Year 2024 Earnings Release Date CLEVELAND, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2024 before the market opens on Thursday, February 27, 2025. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. globenewswire.com - 1 month ago
Sotera Health Chairman and CEO Presents at 43rd Annual J.P. Morgan Healthcare Conference CLEVELAND, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is presenting today at the 43rd Annual J.P. Morgan Healthcare Conference. During the presentation, Chairman and CEO Michael B. Petras, Jr. will be providing an update on Sotera Health's business. globenewswire.com - 2 months ago
Sotera Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference CLEVELAND, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 11:15 a.m. Eastern Time. Mr. Petras, Jon Lyons, Senior Vice President and CFO, and Jason Peterson, Vice President, Investor Relations and Treasurer, will participate in meetings with investors during the conference. globenewswire.com - 3 months ago
Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. globenewswire.com - 3 months ago
Firstlight Management Calls on the Board of Directors of Sotera Health Company to Launch Sale Process for Nelson Labs NEW YORK , Dec. 18, 2024 /PRNewswire/ -- On December 3, 2024, Firstlight Management LP sent a letter to the Board of Directors of Sotera Health Company (NASDAQ: SHC) calling for a sale of its Nelson Labs subsidiary. The full text of the letter is as follows: Dear Members of the Board, As you know, Firstlight Management is a Utah-based investment firm founded by an alumnus of Tiger Management and Leonard Green & Partners. prnewswire.com - 3 months ago
Sotera Health to Share Next Chapter of Growth at 2024 Investor Day CLEVELAND, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, will hold an Investor Day in New York City where Sotera Health's management team will discuss the Company's strategic positioning and outline future growth plans. Management will take questions from a live audience during two question-and-answer sessions. globenewswire.com - 4 months ago
8. Profile Summary

Sotera Health Company SHC

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 2.9 B
Dividend Yield 0.00%
Description Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
Contact 9100 South Hills Boulevard, Broadview Heights, OH, 44147 https://soterahealth.com
IPO Date Nov. 20, 2020
Employees 3000
Officers Ms. Sally R. Turner Chief Human Resources Officer Mr. Alexander Dimitrief J.D. Senior Vice President, General Counsel & Secretary Mr. Robert G. Hauzie Chief Information Officer Mr. Joseph A. Shrawder President of Nelson Labs Ms. Kristin A. Gibbs Chief Marketing Officer Mr. Jonathan M. Lyons Senior Vice President & Chief Financial Officer Mr. Michael B. Petras Jr. Chairman & Chief Executive Officer Mr. Michael P. Rutz President of Sterigenics Mr. William O. Lehmann Jr., J.D., M.B.A. Senior Vice President of Strategy & Corporate Development Ms. Danielle J. Menture Senior Vice President of Global Environmental, Health & Safety and Sustainability